As of the latest Form 4 filed Jul 2, 2026.
What Avalo Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 66 most recent filings for AVTX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-06-30 | Doyle Mittie Chief Medical Officer | SSale | −4.65K | $20.00 | $93.1K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Doyle Mittie, Chief Medical Officer | MExercise | +1.78K | $8.04 | $14.3K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Doyle Mittie, Chief Medical Officer | MExercise | +2.88K | $12.65 | $36.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Doyle Mittie Chief Medical Officer | SSale | −1.45K | $18.00 | $26.1K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Doyle Mittie, Chief Medical Officer | MExercise | +1.45K | $8.04 | $11.7K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Riley Jennifer Chief Strategy Officer | FTax | −588.00 | $13.10 | $7.70K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Doyle Mittie Chief Medical Officer | FTax | −1.08K | $13.10 | $14.2K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Sullivan Christopher Ryan Chief Financial Officer | FTax | −138.00 | $13.10 | $1.81K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | VARKI PAUL Chief Legal Officer | FTax | −1.08K | $13.10 | $14.2K | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-28 | Doyle Mittie Chief Medical Officer | SSale | −679.00 | $16.00 | $10.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-05-28 | Doyle Mittie, Chief Medical Officer | MExercise | +679.00 | $8.04 | $5.46K | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Riley Jennifer Chief Strategy Officer | AAward | +34.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Doyle Mittie Chief Medical Officer | AAward | +43.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Sullivan Christopher Ryan Chief Financial Officer | AAward | +39.9K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | VARKI PAUL Chief Legal Officer | AAward | +24.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | NEIL GARRY ARTHUR Chief Executive Officer | AAward | +100K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Doyle Mittie Chief Medical Officer | SSale | −3.00K | $18.76 | $56.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Doyle Mittie, Chief Medical Officer | MExercise | +3.00K | $12.65 | $38.0K | Yes (planned) | Form 4 ↗ |
| 2026-05-11 | 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | SSale | −18.6K | $24.12 | $449K | Yes (planned) | Form 4 ↗ |
| 2026-05-11 | 2026-05-07 | Sullivan Christopher Ryan, Chief Financial Officer | MExercise | +18.6K | $9.88 | $184K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie Chief Medical Officer | SSale | −10.1K | $22.88 | $230K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie, Chief Medical Officer | SSale | −19.0K | $22.41 | $426K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie, Chief Medical Officer | SSale | −44.9K | $21.20 | $953K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie, Chief Medical Officer | SSale | −5.00K | $19.65 | $98.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie, Chief Medical Officer | SSale | −27.5K | $18.03 | $496K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie, Chief Medical Officer | MExercise | +28.6K | $8.04 | $230K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Doyle Mittie, Chief Medical Officer | MExercise | +77.9K | $12.65 | $985K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | SSale | −8.90K | $22.57 | $201K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −9.22K | $21.37 | $197K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −2.70K | $20.76 | $56.1K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −12.3K | $19.28 | $238K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −13.8K | $18.55 | $257K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Sullivan Christopher Ryan, Chief Financial Officer | MExercise | +47.0K | $8.04 | $378K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | Chan Mitchell Director | SSale | −3.17K | $22.88 | $72.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL Chief Legal Officer | SSale | −400.00 | $23.71 | $9.48K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL, Chief Legal Officer | SSale | −9.25K | $22.70 | $210K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL, Chief Legal Officer | SSale | −22.8K | $21.22 | $485K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL, Chief Legal Officer | SSale | −5.20K | $19.78 | $103K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL, Chief Legal Officer | SSale | −37.4K | $18.91 | $707K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL, Chief Legal Officer | MExercise | +12.6K | $8.04 | $101K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-06 | VARKI PAUL, Chief Legal Officer | MExercise | +62.5K | $13.43 | $839K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Doyle Mittie Chief Medical Officer | SSale | −1.68K | $16.00 | $26.9K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Doyle Mittie, Chief Medical Officer | MExercise | +679.00 | $8.04 | $5.46K | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Doyle Mittie, Chief Medical Officer | MExercise | +1.00K | $12.65 | $12.7K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Sullivan Christopher Ryan Chief Financial Officer | SSale | −8.46K | $13.23 | $112K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −8.46K | $13.09 | $111K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-06 | Doyle Mittie Chief Medical Officer | SSale | −3.97K | $18.01 | $71.5K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-06 | Doyle Mittie, Chief Medical Officer | MExercise | +3.97K | $12.65 | $50.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-03 | 2026-04-02 | Sullivan Christopher Ryan Chief Financial Officer | SSale | −1.78K | $17.57 | $31.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-03 | 2026-04-02 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −6.20K | $17.02 | $106K | Yes (planned) | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Doyle Mittie Chief Medical Officer | SSale | −679.00 | $16.00 | $10.9K | Yes (planned) | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Doyle Mittie, Chief Medical Officer | MExercise | +679.00 | $8.04 | $5.46K | Yes (planned) | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Sullivan Christopher Ryan Chief Financial Officer | SSale | −7.48K | $16.83 | $126K | Yes (planned) | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Sullivan Christopher Ryan, Chief Financial Officer | SSale | −500.00 | $15.86 | $7.93K | Yes (planned) | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | Truex Samantha Director | MExercise | +3.17K | — | — | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | Goldman Jonathan Director | MExercise | +3.17K | — | — | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | KANTOFF AARON Director | MExercise | +3.17K | — | — | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | Sullivan Christopher Ryan Chief Financial Officer | FTax | −8.24K | $13.89 | $114K | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | Sullivan Christopher Ryan, Chief Financial Officer | MExercise | +24.2K | — | — | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | Chan Mitchell Director | MExercise | +3.17K | — | — | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | NEIL GARRY ARTHUR Chief Executive Officer | FTax | −21.9K | $13.89 | $304K | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | NEIL GARRY ARTHUR, Chief Executive Officer | MExercise | +64.9K | — | — | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-28 | KAPLAN GILLA Director | MExercise | +3.17K | — | — | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Doyle Mittie Chief Medical Officer | SSale | −25.5K | $16.15 | $412K | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Doyle Mittie, Chief Medical Officer | MExercise | +5.99K | $8.04 | $48.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Doyle Mittie, Chief Medical Officer | MExercise | +19.5K | $12.65 | $247K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also AVTX’s full analysis or the market-wide insider trading feed. The tabs above jump to AVTX’s other SEC data.
Source: SEC Form 4 filings for AVTX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.